Statement: Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia.
Primary_evidence: Adverse Events 1:   Total: 8/113 (7.08%)   Febrile neutropenia [1]0/113 (0.00%)   Anemia with trombocytopenia  0/113 (0.00%)   Neutropenia  1/113 (0.88%)   Paroxism of atrial fibrillation  0/113 (0.00%)   Ventricular extrasystolone RYAN-1  0/113 (0.00%)   Gastrointestinal hemorrhage  1/113 (0.88%)   Death for unknown reason  1/113 (0.88%)   Diarrhea with vomiting and weakness  0/113 (0.00%) Adverse Events 2:   Total: 13/110 (11.82%)   Febrile neutropenia [1]1/110 (0.91%)   Anemia with trombocytopenia  1/110 (0.91%)   Neutropenia  1/110 (0.91%)   Paroxism of atrial fibrillation  2/110 (1.82%)   Ventricular extrasystolone RYAN-1  1/110 (0.91%)   Gastrointestinal hemorrhage  0/110 (0.00%)   Death for unknown reason  1/110 (0.91%)   Diarrhea with vomiting and weakness  1/110 (0.91%)